-+ 0.00%
-+ 0.00%
-+ 0.00%

Autolus presents up to 20-month follow-up data from Phase 1 CARLYSLE lupus trial at ACR Convergence 2026

PUBT·10/05/2026 12:36:24
Listen to the news
Autolus presents up to 20-month follow-up data from Phase 1 CARLYSLE lupus trial at ACR Convergence 2026
  • Autolus Therapeutics flagged longer-term follow-up data from its Phase 1 CARLYSLE trial of obe-cel in severe refractory systemic lupus erythematosus.
  • Results have not been presented yet; the update is slated for a poster session at ACR Convergence 2026 on Nov. 10.
  • The readout is expected to reinforce the therapy’s safety and efficacy profile in adults, with early follow-up in adolescents.
  • The update extends durability evidence to as long as 20 months in adult patients, a key marker for autoimmune expansion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autolus Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050830PRIMZONEFULLFEED9839494) on October 05, 2026, and is solely responsible for the information contained therein.